BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 10026993)

  • 41. Polymorphisms of xenobiotic metabolizing enzymes in bladder cancer patients of the Semmelweis University Budapest, Hungary.
    Ebbinghaus D; Bánfi G; Selinski S; Blaszkewicz M; Bürger H; Hengstler JG; Nyirády P; Golka K
    J Toxicol Environ Health A; 2017; 80(7-8):423-429. PubMed ID: 28696897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: study of population from a high- incidence area in north China.
    Wang LD; Zheng S; Liu B; Zhou JX; Li YJ; Li JX
    World J Gastroenterol; 2003 Jul; 9(7):1394-7. PubMed ID: 12854128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma.
    Tiemersma EW; Omer RE; Bunschoten A; van't Veer P; Kok FJ; Idris MO; Kadaru AM; Fedail SS; Kampman E
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):785-91. PubMed ID: 11440964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population.
    Torkaman-Boutorabi A; Hoormand M; Naghdi N; Bakhshayesh M; Milanian I
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1207-11. PubMed ID: 17880378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes.
    Antonova O; Toncheva D; Grigorov E
    J BUON; 2015; 20(6):1397-406. PubMed ID: 26854433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.
    Krajinovic M; Ghadirian P; Richer C; Sinnett H; Gandini S; Perret C; Lacroix A; Labuda D; Sinnett D
    Int J Cancer; 2001 Apr; 92(2):220-5. PubMed ID: 11291049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection.
    Joseph T; Chacko P; Wesley R; Jayaprakash PG; James FV; Pillai MR
    Gynecol Oncol; 2006 Jun; 101(3):411-7. PubMed ID: 16360200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking.
    Yoshida K; Osawa K; Kasahara M; Miyaishi A; Nakanishi K; Hayamizu S; Osawa Y; Tsutou A; Tabuchi Y; Shimada E; Tanaka K; Yamamoto M; Takahashi J
    Asian Pac J Cancer Prev; 2007; 8(3):438-44. PubMed ID: 18159984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modifying Effect of Smoking on GSTM1 and NAT2 in Relation to the Risk of Bladder Cancer in Mongolian Population: A Case-Control Study.
    Avirmed S; Khuanbai Y; Sanjaajamts A; Selenge B; Dagvadorj BU; Ohashi M
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2479-2485. PubMed ID: 34452561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas.
    Wideroff L; Vaughan TL; Farin FM; Gammon MD; Risch H; Stanford JL; Chow WH
    Cancer Detect Prev; 2007; 31(3):233-6. PubMed ID: 17646057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia.
    Rouissi K; Ouerhani S; Hamrita B; Bougatef K; Marrakchi R; Cherif M; Ben Slama MR; Bouzouita M; Chebil M; Ben Ammar Elgaaied A
    Pathol Oncol Res; 2011 Dec; 17(4):879-86. PubMed ID: 21647780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer.
    Gates MA; Tworoger SS; Terry KL; Titus-Ernstoff L; Rosner B; De Vivo I; Cramer DW; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2436-44. PubMed ID: 18768514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population.
    Hlavata I; Vrana D; Smerhovsky Z; Pardini B; Naccarati A; Vodicka P; Novotny J; Mohelnikova-Duchonova B; Soucek P
    Oncol Rep; 2010 Nov; 24(5):1347-53. PubMed ID: 20878130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide.
    Pastorelli R; Guanci M; Cerri A; Negri E; La Vecchia C; Fumagalli F; Mezzetti M; Cappelli R; Panigalli T; Fanelli R; Airoldi L
    Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):703-9. PubMed ID: 9718223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking.
    Tsukino H; Nakao H; Kuroda Y; Imai H; Inatomi H; Osada Y; Katoh T
    Eur J Cancer Prev; 2004 Dec; 13(6):509-14. PubMed ID: 15548945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms.
    Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
    Oncol Rep; 2004 Oct; 12(4):773-9. PubMed ID: 15375499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.
    Zupa A; Sgambato A; Bianchino G; Improta G; Grieco V; LA Torre G; Campisi B; Traficante A; Aieta M; Cittadini A
    Anticancer Res; 2009 May; 29(5):1709-14. PubMed ID: 19443391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Susceptibility of lung cancer with polymorphisms of CYP1A1, GSTM1, GSTM3, GSTT1 and GSTP1 genotypes in the population of Inner Mongolia region.
    Jiang XY; Chang FH; Bai TY; Lv XL; Wang MJ
    Asian Pac J Cancer Prev; 2014; 15(13):5207-14. PubMed ID: 25040976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
    Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
    Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
    Suzuki S; Muroishi Y; Nakanishi I; Oda Y
    J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.